Genomics technology has paved the way for a global and unbiased quantitative and qualitative assessment of the immune response. We have developed an Immune Array platform based on whole genome microarray analysis and a transcriptomic approach that is well suited to identify the mechanisms that lead to protective immunity induced by vaccines. We have previously used this platform to describe the very early induction (3 to 7 days) of a network of transcription factors that precede the development of highly integrated innate and adaptive immune responses induced by the Yellow Fever vaccine. In the Systems Biology Core E of this consortium, we aim to (i) provide a centralized sample, reporting, and data management and distribution framework, (ii) perform a comprehensive systems biology assessment of SIV vector-mediated innate and adaptive immune responses, (iii) provide rigorous biostatistical processing and power analysis of microarray and quantitative RT-PCR (QPCR) analysis, and (iv) provide projects and core-integrated immune correlate analysis for SIV vector immune characterization, selection, and study.
The aims of the core will be met via our commercial grade Laboratory Information Management System (LIMS), our SOP-driven, high-throughput. Immune Array platform for microarray analysis, our standardized, semiautomated bioinformatic reporting, and our template-driven data mapping of biological contexts/outcomes to integrate multiple projects and multiple OMIC platforms. We will use these leading edge technologies and bioinformatic strategies to assess the transcriptomic signatures that define early SIV-mediated host responses following different routes of mucosal challenge and the impact of SIV vector-mediated protection.
The impetus to provide an effective HIV vaccine has engaged multiple investigators across the globe and has largely been unsuccessful to date. This program project attempts to utilize novel vaccination strategies and novel technological approaches to develop vaccines in non-human primate models. The Systems Biology Core will use leading technologies in these proposed studies to develop novel vaccines that will eventually be tested in clinical trials in humans.
|Okoye, Afam A; Hansen, Scott G; Vaidya, Mukta et al. (2018) Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat Med 24:1430-1440|
|Abbink, Peter; Larocca, Rafael A; Dejnirattisai, Wanwisa et al. (2018) Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. Nat Med 24:721-723|
|Walters, Lucy C; Harlos, Karl; Brackenridge, Simon et al. (2018) Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat Commun 9:3137|
|Aid, Malika; Abbink, Peter; Larocca, Rafael A et al. (2017) Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell 169:610-620.e14|
|Abbink, Peter; Larocca, Rafael A; Visitsunthorn, Kittipos et al. (2017) Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med 9:|
|Keele, Brandon F; Li, Wenjun; Borducchi, Erica N et al. (2017) Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun 8:15740|
|Barouch, Dan H; Thomas, Stephen J; Michael, Nelson L (2017) Prospects for a Zika Virus Vaccine. Immunity 46:176-182|
|Ackerman, Margaret E; Barouch, Dan H; Alter, Galit (2017) Systems serology for evaluation of HIV vaccine trials. Immunol Rev 275:262-270|
|McMichael, Andrew J; Picker, Louis J (2017) Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol 46:75-81|
|Tomalka, Jeffrey; Ghneim, Khader; Bhattacharyya, Sanghamitra et al. (2016) The sooner the better: innate immunity as a path toward the HIV cure. Curr Opin Virol 19:85-91|
Showing the most recent 10 out of 57 publications